Registration is now open for the Muscular Dystrophy Association’s 2022 MDA Clinical & Scientific Conference, being held March 13-16, 2022 both in person at the Gaylord Opryland Resort and Convention Center in Nashville, Tennessee, and via live stream.
“We are looking forward to our first fully hybrid format with a very rich and wide breadth of content for clinicians and researchers.”
— Sharon Hesterlee, PhD, EVP, Chief Research Officer at MDA
The 2022 conference will explore all aspects of pre-clinical, translational, and clinical research and care across neuromuscular diseases (NMD) to support the development of better care and treatments for our community. It will present concurrent clinical and translational sessions on topics highlighting:
- New Gene Discoveries in NMD
- Facilitating Multi-Practice Collaboration to Optimize Patient Care
- Impact of Gene Transfer Therapy on Long-term Multidisciplinary Care
- Evolution of Ultra-Rare Disease Clinical Trial Design
“This is a time of great promise and rapid advances in neuromuscular research and treatment. Our conference brings together the most influential scientists from academia and industry, as well as clinicians and patient advocacy groups, to learn the latest developments in therapies and care that will transform the lives of people with neuromuscular disease.”
— Donald S. Wood, PhD, President & CEO, at MDA
To promote greater representation of the neuromuscular disease community at the conference, MDA is encouraging participation by patient advocates and patient advocacy organizations, who will receive a reduced registration fee and have access to all sessions.
All COVID-19 safety precautions will be taken and enforced at the conference.
For additional information and to register, visit MDA Conference.
The abstract submission portal is also open. Oral presentations will be selected from abstracts submitted by the December 31, 2021 deadline. For more information and to submit, visit the Abstract Submission Portal.
[Source(s): Muscular Dystrophy Association, PR Newswire]